Akèy › Amiloidoz ereditè ki gen rapò ak transthyretin
Etid klinik pou Amiloidoz ereditè ki gen rapò ak transthyretin ap rekrite nan Etazini
9 etid pou Amiloidoz ereditè ki gen rapò ak transthyretin ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Los Angeles, CA5 etid
- New York City, NY5 etid
- Portland, OR4 etid
- Boston, MA4 etid
- Philadelphia, PA4 etid
- Baltimore, MD4 etid
- San Diego, CA4 etid
- Dallas, TX4 etid
- Durham, NC4 etid
- Jacksonville, FL3 etid
- Chicago, IL3 etid
- Richmond, VA3 etid
- New Haven, CT3 etid
- Washington, DC3 etid
- Houston, TX3 etid
- Cleveland, OH3 etid
- Rochester, MN3 etid
- Kansas City, MO3 etid
- St. Louis, MO3 etid
Pa eta
- Connecticut3 etid
- Distrik Columbia3 etid
- Florid3 etid
- Illinois3 etid
- Kalifòni5 etid
- Maryland4 etid
- Massachusetts4 etid
- Minnesota3 etid
- Missouri4 etid
- New York5 etid
- North Carolina4 etid
- Ohio4 etid
- Oregon4 etid
- Pennsylvania4 etid
- South Carolina3 etid
- Texas5 etid
- Virginia3 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Ap rekriteEtid obsèvasyon
Laj 18 a 130 · Tout sèks · Mizajou Sep 23, 2026 · NCT06465810Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07654855ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 8, 2026 · NCT04561518Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Ap rekrite
Laj 65 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT05577819Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Ap rekriteEtid obsèvasyon
Laj 30 a 80 · Tout sèks · Mizajou Aug 31, 2026 · NCT05489549Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Aug 4, 2026 · NCT06563895Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Jul 29, 2026 · NCT07695701Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Ap rekriteFaz 2
Laj 40 a 90 · Tout sèks · Mizajou Apr 13, 2026 · NCT05758493MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Ap rekriteFaz 3
Laj 18 a 90 · Tout sèks · Mizajou Mar 27, 2026 · NCT06128629Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.